Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of the Feasibility and Safety of SuraL nervE Tissue Grafting to the Substantia nigrA in Patients With Synucleinopathies (LEAP)

NCT06683365 is registered in ClinicalTrials.gov with Craig van Horne, MD, PhD as lead sponsor.

NCT NCT06683365
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06683365 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of the Feasibility and Safety of SuraL nervE Tissue Grafting to the Substantia nigrA in Patients With Synucleinopathies (LEAP)
Lead sponsor
Craig van Horne, MD, PhD
Phase
Phase 1
Overall status
Recruiting
Start date
February 25, 2025
Completion date
December 2, 2030
Enrollment
7 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple system atrophy, parkinsons disease